Current position

Tom Russo’s AbbVie (ABBV) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Gardner Russo & Quinn · formerly Gardner Russo & GardnerVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ1 2013Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares88.25KHighest verified quarter-end share count
Quarters reported53Verified quarters with shares above zero
What happened?

Gardner Russo & Quinn · formerly Gardner Russo & Gardner first reported AbbVie in Q1 2013. The reported position was increased and reduced across later filings. Gardner Russo & Quinn · formerly Gardner Russo & Gardner currently reports 12.41K shares. The latest verified filing showed: No change.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2026
No change12.41K shares reported
Filing context

Quarter-end price $251.64 · Estimated holding basis $89.04

Q4 2024
Sold 0.8% of the position−100 shares · 12.41K shares remained
Filing context

Quarter-end price $177.70 · Estimated holding basis $89.04

Q4 2023
Sold 0.6% of the position−73 shares · 12.51K shares remained
Filing context

Quarter-end price $154.97 · Estimated holding basis $89.04

Q3 2023
Sold 0.06% of the position−8 shares · 12.58K shares remained
Filing context

Quarter-end price $149.06 · Estimated holding basis $89.04

Q2 2023
Sold 0.2% of the position−19 shares · 12.59K shares remained
Filing context

Quarter-end price $134.73 · Estimated holding basis $89.04

Q2 2022
Sold 2.3% of the position−300 shares · 12.61K shares remained
Filing context

Quarter-end price $153.13 · Estimated holding basis $89.04

30 unchanged quarters are collapsed by default.

Portfolio importance

How important is AbbVie in Gardner Russo & Quinn · formerly Gardner Russo & Gardner’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight0.0%Q2 2026
Current rank#30of 85 reported positions
Peak portfolio weight0.1%Q4 2014
Best historical rank#30Q1 2026
At peak importanceQ4 2014
ABBV
0.1%
Largest holding
10.4%
Cross-investor discovery

Who else owns AbbVie?

Also reported by 2 other tracked investors in their latest verified filings.

Joel GreenblattGotham Asset Management
ABBV0.1% of reported portfolio
Ray DalioBridgewater Associates, LP
ABBV0.0% of reported portfolio
Explore AbbVie across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$257.122026-09-11

Market context only; not an investor transaction price.

Latest filing quarter-end price$251.64Q2 2026

Derived from validated reported value and shares where supported.

Estimated holding basis$89.04Historical reference — not actual purchase price

Calculated from supported filing history.

Latest verified investor filingQ2 2026 · filed 2026-08-13
Open SEC filing ↗

View AbbVie stock page →

This tracker follows the current SEC filer, Gardner Russo & Quinn LLC (formerly Gardner Russo & Gardner), not Tom Russo’s personal brokerage account. Form 13F reports quarter-end U.S.-listed positions and certain options, but it does not reveal exact trade dates, execution prices, short positions or the purpose of an option position.